Online inquiry

IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6870MR)

This product GTTS-WQ6870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets KLKB1 gene. The antibody can be applied in Hereditary Angioedema (HAE) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000892.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3818
UniProt ID P03952
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12229MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ15369MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ1411MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ6156MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ11870MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ12051MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ10635MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ12528MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW